Wells Fargo & Company Lowers Globus Medical (NYSE:GMED) Price Target to $99.00

Globus Medical (NYSE:GMED) had its price target decreased by Wells Fargo & Company from $103.00 to $99.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 20.64% from the company’s current price.

A number of other equities analysts also recently commented on GMED. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Needham & Company LLC lifted their price target on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Stock Up 1.2%

NYSE:GMED traded up $0.98 during trading hours on Friday, reaching $82.06. 570,931 shares of the stock were exchanged, compared to its average volume of 1,477,988. The firm has a 50 day simple moving average of $79.33 and a 200-day simple moving average of $85.25. Globus Medical has a 52 week low of $54.15 and a 52 week high of $101.40. The stock has a market capitalization of $11.14 billion, a P/E ratio of 19.14, a P/E/G ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. During the same quarter last year, the firm earned $0.86 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts expect that Globus Medical will post 4.74 earnings per share for the current year.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.38% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. Elevation Wealth Partners LLC increased its holdings in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after acquiring an additional 305 shares during the period. Advisory Services Network LLC acquired a new position in Globus Medical during the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, versus analyst estimates near $1.10-$1.12, while revenue reached $789.6 million, ahead of the $782.9 million consensus. Earnings increased from $0.86 per share a year earlier, and revenue rose 5.9% year over year. Globus Medical Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year earnings guidance was raised above Wall Street expectations: Management provided fiscal 2026 EPS guidance of $4.95-$5.05, compared with the $4.74 analyst consensus. The higher outlook suggests improved confidence in profitability and execution. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: TD Cowen maintained a Buy rating and $115 price target. Analyst Mathew Blackman cited reaccelerating spine growth, strong earnings power and robust research-and-development investment as reasons for the constructive view. Globus Medical Earns Buy Rating
• Neutral Sentiment: Revenue guidance was broadly in line with consensus at approximately $3.2 billion for fiscal 2026, meaning the main guidance-driven upside came from the improved EPS outlook rather than a sales forecast increase.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.